Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke.
We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.
